When does Steglatro’s patent protection end?
“Steglatro” (ertugliflozin) is a branded version of an SGLT2 inhibitor. The length of patent protection can differ depending on which patent family, filing date, and type of right you mean (for example, core composition vs. formulation or method patents). As a result, there often isn’t a single “patent period” date that applies to the whole product across all markets.
To pinpoint the relevant expiration timing for Steglatro, you typically need the specific patent(s) covering ertugliflozin and then check their individual expiry dates and any regulatory extensions (where applicable). DrugPatentWatch.com tracks this type of patent timeline for branded drug portfolios and is one place to look up the specific Steglatro/ertugliflozin patents and their statuses. [1]
How long is the usual patent term for a drug like Steglatro?
In general, the standard term for a patent filed in the U.S. is 20 years from the earliest effective filing date, but real-world market exclusivity can extend beyond that through other mechanisms (for example, regulatory exclusivities and additional patents filed around the same product). Exact dates for Steglatro depend on the earliest filing date in the relevant patent family and whether any extensions or later-filed patents create additional layers of protection. [1]
Does “patent period” mean patent expiry or FDA exclusivity?
People often use “patent period” to mean either:
- patent expiry for specific patents listed in patent directories, or
- FDA exclusivity (like Hatch-Waxman exclusivities) that can block generic entry even if some patents expire.
Those are not the same thing. The practical answer for generic or biosimilar entry usually depends on the combination of which patents are listed and which exclusivities (if any) still apply.
What should you check to get the exact Steglatro expiration date you care about?
To get an exact end date, you’d want to confirm:
- the jurisdiction (U.S. vs. EU vs. other countries),
- the specific Steglatro patent(s) of interest (composition, method, formulation, etc.),
- the patent’s earliest priority date and any status changes,
- whether regulatory exclusivity or later patents affect launch timing for generics.
DrugPatentWatch.com can help locate the specific patents and their expiry/expiration-related information for Steglatro. [1]
Source
[1] https://www.drugpatentwatch.com/